You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. A New Non-Invasive Approach for Accessing Pulmonary Arterial Stiffness in Patients with Pulmonary Hypertension

    SBC: Arcus-Med LLC            Topic: NHLBI

    Pulmonary hypertensionPHis a disease affecting approximatelyof the general population that is characterized by abnormally elevated mean pulmonary artery pressuremPAPand pulmonary vascular resistancePVRIf left untreatedPH can ultimately lead to right heart failure and deathCurrent diagnostic approaches utilize invasive right heart catheterizationRHCto measure mPAP and PVREarly detection of PH leads ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Development of Small Molecules that Enhance the Delivery and the Pharmacological Effects of Oligonucleotides

    SBC: Initos Pharmaceuticals LLC            Topic: 999

    DESCRIPTION provided by applicant Antisense and siRNA oligonucleotides offer the promise of highly precise manipulation of genes involved in disease pathogenesis However despite the investment of enormous resources that promise has been fulfilled to only a limited degree A key impediment to oligonucleotide based therapeutics is the difficulty in delivering these large highly polar molecule ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  3. HLS Cyclic CAR peptide a targeted therapy for pulmonary hypertension

    SBC: VASCULAR BIOSCIENCES, INC.            Topic: NHLBI

    PUBLIC ABSTRACT This project in response to announcement HLS describes a development program for CARSKNKDC CAR a synthetic cyclic peptide that selectively targets diseased pulmonary vascular endothelium and enhances the therapeutic effect of vasodilator therapies for the treatment of pulmonary hypertension PH PH is a disorder of elevated pulmonary vascular resistance characterized by ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  4. IRE1beta Inhibitors: Novel Therapeutics to Manage Excess Mucus in Asthma

    SBC: Irex Pharma LLC            Topic: NIAID

    PROJECT SUMMARY Overmillion Americans have asthmawhich places an economic burden on the U Sof $billionAirway mucus overproduction is a hallmark of asthmaand the quantity and tenacity of mucus are increased during airway exacerbationsMucolytics degrade mucusbut do not reduce its productionAlthough corticosteroids and other anti inflammatory therapies indirectly decrease mucus productionand anti cho ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Development of a predictive moderate throughput assay to screen novel Designer Proline-rich antimicrobial peptide Chaperone protein inhibitors (DPCs) against multi-drug resistant pathogen

    SBC: Arrevus, Inc.            Topic: NIAID

    Multi drug resistantMDRbacterial infections represent a significant threat to public healthIt is estimated that the impact of antibiotic resistance will continue to grow resulting in a global economic burden of $trillion and causingmillion deaths annuallyMany of the therapeutics currently under development represent traditional antibiotic approaches or next generation antibiotics that will likely ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Use of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating antibiotic resistant pneumonia

    SBC: Arrevus, Inc.            Topic: NIAID

    Project SummaryInfectious disease is the third leading cause of death in the United Statesand hospital acquired infectionsHAIsin particular affectmillion patients annuallyThe most common type of HAI is pneumoniaoften caused by multi drug resistantMDRpathogens such as Staphylococcus aureusPseudomonas aeruginosaKlebsiella pneumoniaeEscherichia coliand Acinetobacter baumanniiRates of antibiotic resis ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Development of a POEGMA Aptamer rapid onset anticoagulant that eliminates antigenicity to anti PEG antibodies

    SBC: Gateway Bio, Inc.            Topic: NHLBI

    ABSTRACT The objective of this STTR proposal is to reformulate a promising PEG aptamer rapid onset anticoagulant ROA by applying a novel PEG like POEGMA polymer brush technology capable of eliminating anti PEG antigenicity The importance of this proposal is highlighted by the early termination of a recent Phase III clinical trial of the original PEG aptamer conjugate in which severe allergic ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Delivery of pathogen trapping antibodies for vaginal protection

    SBC: MUCOMMUNE, LLC            Topic: NIAID

    DESCRIPTION provided by applicant Despite immense efforts in behavioral interventions to promote safer sexual practices sexually transmitted infections STIs continue to be a pandemic worldwide Unfortunately there are no effective vaccines or microbicides for the majority of STIs A pathogen specific safe effective and discreet vaginal microbicide that does not require daily or sex associ ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Pudendal neuromodulation for incontinence and sphincter dyssynergia after spinal injury

    SBC: Dignify Therapeutics LLC            Topic: 106

    Spinal cord injurySCIfrequently produces severelife long bladder and bowel dysfunction that result in urinary and fecal incontinenceas well as sphincter dyssynergia that causes urinary retention and fecal impactionCurrent standard of care for incontinence consists of adult diaperswhile bladder and bowel voiding require multiple times daily catheterization of the bladder and regular digital extract ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Automated CRISPR Screening Using the CellRaft Technology

    SBC: Cell Microsystems, Inc.            Topic: 400

    Project SummaryGenome wide functional genetics has been recently made possible by pooled library based CRISPR Casgene editing technologyBy randomly knocking out thousands of geneslarge scale screens can be conducted for functional geneticsdrug sensitivity and other phenotypesCurrently howeverthis forward genetic approach is largely relegated to live dead screens in mammalian cellsImproving the sop ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government